Introduction
Chromosome 3p shows a high frequency of allelic loss in nasopharyngeal carcinoma (NPC) tumors and has an important role in NPC suppression (Mutirangura et al., 1997; Senchenko et al., 2004; Yau et al., 2006; Cheung et al., 2008) . NotI chromosome 3-specific microarray profiling is useful for screening for genes inactivated by deletion and/or hypermethylation. Comparative hybridization of tumorigenic NPC cell lines versus an immortalized nasopharyngeal (NP) epithelial cell line and also of previously established and characterized tumor-suppressive chromosome 3 microcell hybrids (MCHs) versus tumorigenic MCH tumor segregants (Cheng et al., 1998) can be used to identify chromosome 3 candidate tumor-suppressor gene (TSGs). A candidate gene, Fibulin-2 (FBLN2), which showed frequent methylation or deletion in NPC cell lines and tumor segregants, was thus, identified.
FBLN2, located at chromosome 3p25.1, belongs to the fibulin family of extracellular matrix (ECM) glycoproteins. Fibulins interact with a variety of extracellular ligands in diverse ECM structures, including basement membrane, elastic fibers and microfibrils (de Vega et al., 2009) . These interactions may be critical in determining cell movement, proliferation and angiogenesis. Fibulins are believed to have important roles in cancer development because of these diverse interactions (Gallagher et al., 2005) .
Several studies have demonstrated the association between FBLN2 inactivation and tumor progression. Loss of FBLN2 protein expression is observed in breast cancer cell lines and tumors (Yi et al., 2007) . Frequent FBLN2 methylation was detected in childhood acute lymphoblastic leukemia (Dunwell et al., 2009) . Epigenetic studies showed FBLN2 is frequently methylated in breast, colorectal and lung cancers (Hill et al., 2010) . Genome-wide Human Mapping 10K Array analysis showed that the chromosome 3p25.1 region, where FBLN2 maps, is often deleted in esophageal squamous cell carcinoma patients (Chattopadhyay et al., 2010) . These findings suggest FBLN2 is a potential TSG, but its functional role in tumor suppression is not well characterized.
FBLN2 is a large 190 kDa protein consisting of four domains, the N-terminal domain, three anaphylatoxin modules, a tandem of epidermal growth factor-like repeats most of which have a calcium-binding domain and the C-terminal fibulin-type module (Gallagher et al., 2005) . The third epidermal growth factor-like domain in calcium-binding epidermal growth factor-like repeated modules of FBLN2 is either present or absent as a result of alternative splicing in exon 9; this suggests that both isoforms may be protein coding, as there is only a single deletion of the epidermal growth factor-like domain. Both the long and short FBLN2 isoforms are found in humans and mice, but no comparative functional studies have been reported on either isoform (Grassel et al., 1999) .
FBLN2 is highly expressed during epithelial-mesenchymal transformation in the endocardial cushion matrix, aortic arch vessels and coronary vessels during embryonic heart development (Zhang et al., 1995; Tsuda et al., 2001) . Thus, FBLN2 may be associated with blood vessel formation and cell migration during embryonic heart development. Furthermore, FBLN2 is upregulated during skin wound healing and returns to normal levels when wound repair is completed (Zhang et al., 1995; Fassler et al., 1996) , suggesting that FBLN2 may be involved in regulating cell mobility during tissue repair. In this study, in vitro and in vivo functional characterization reveals an important tumor-suppressive role of FBLN2 in cell proliferation, migration, invasion and angiogenesis. This provides the first functional and molecular characterization of FBLN2 in cancer progression.
Results
Identification of a promoter hypermethylated and frequently deleted candidate TSG, FBLN2, by NotI microarray screening The NotI chromosome 3 genomic microarray screening of methylated and deleted genes present in NPC cell lines and MCHs compared with an immortalized NP epithelial cell line and MCH-tumor segregants, respectively, identified five candidate TSGs (FBLN2, TME-M45A, ZIC4, GPR149 and ETV5) with at least 50% downregulated expression levels in NPC cell lines and biopsies (Table 1 ). All NPC cell lines showed downregulation for the FBLN2, GPR149 and ZIC4 genes. When tumor tissues were also screened to determine the extent of downregulation of these genes in clinical specimens, then all three genes showed over 46% downregulation (Table 1) . As a result of the frequent methylation of FBLN2 detected in other cancers and its important roles in ECM (Dunwell et al., 2009; de Vega et al., 2009; Hill et al., 2010) , it was chosen for further study.
Significant downregulation of both FBLN2 isoforms was observed in all seven NPC cell lines by RT-PCR. The short FBLN2 isoform (FBLN2S) is dominantly expressed in the immortalized NP cell lines (Figure 1a) , while the long FBLN2 isoform (FBLN2L) was barely detectable. FBLN2S protein expression is downregulated in both cell lysates and conditioned media of all NPC cell lines (Figure 1b) . In all, 14 of 30 NPC biopsies (46.7%) show FBLN2 downregulation, when compared with their corresponding paired non-tumor tissues (Figure 1c ). FBLN2 isoform expression was further investigated in eight FBLN2 downregulated NPC biopsies. All non-tumor tissues expressed FBLN2S, but only two of these tissues also weakly expressed FBLN2L ( Figure 1d ). As FBLN2S is the dominantly expressed isoform in the immortalized NP cell lines and non-tumor tissues, subsequent functional studies were performed with this short isoform of FBLN2.
To validate the mechanism of FBLN2 inactivation in NPC and verify the NotI microarray results, 92 CpG sites in the FBLN2 promoter (Supplementary Figure S1) were investigated by clonal bisulfite genomic sequencing of NPC cell lines and FBLN2 downregulated tumors. A high methylation index (MI) of 40-81.1% was detected in NPC cell lines, HONE1 and HNE1, and tumors, T81 and T89, compared with the immortalized NP cell lines, NP460 and NP69, and corresponding nontumor tissues, respectively, showing a MI of 2.2-7.4% ( Figure 2a, Supplementary Figure S2 ). Further analysis of promoter hypermethylation was performed by using methylation-specific PCR primers overlapping with the CpG islands, which show frequent hypermethylation. Methylated alleles are only detected in FBLN2 downregulated NPC cell lines and tumors, whereas only the unmethylated allele is detected in the immortalized NP cell lines and corresponding non-tumor tissues ( Figure 2b ). All NPC cell lines showed re-expression of FBLN2S after treatment with the demethylation drug, 5-aza-2 0 deoxycytidine. In contrast, noticeable re-expression of the FBLN2L was only observed in (Figure 2c ). These findings demonstrate the importance of promoter hypermethylation for FBLN2S silencing in NPC and its importance in NPC. Continuous homozygosity in a region extending from D3S2403 to D3S1585 in the chromosome 3p25 region was detected in HK1, CNE1, and C666 ( Figure 2d ). In contrast, the two immortalized NP cell lines, NP69 and NP460 are heterozygous (Figure 2d ). These results are consistent with genomic deletion being another important mechanism for FBLN2S silencing during cancer development.
Re-expression of FBLN2S suppresses in vitro colony formation and in vivo tumor growth In order to investigate the functional role of FBLN2S, a colony formation assay was performed. A significantly reduced number of colonies (67.1 to 95.1%) was observed in all FBLN2S transiently transfected cell lines tested (Figure 1e) .
The functional role of tetracycline-regulated FBLN2S in NPC was studied after stably transfecting FBLN2S into the HONE1-2 cell line. Three clones (S8, S15, S18) showing FBLN2S doxycycline (Dox)-regulated expression at both the RNA and protein levels were chosen for further studies. By quantitative reverse transcriptase-PCR (Q-PCR), all three FBLN2S stable transfectants in the absence of Dox showed physiologically normal expression levels of FBLN2S compared with the immortalized NP cell lines. Doxcycline repressed the expression of the transgene FBLN2 to vector-alone levels ( Figures 3a and b) ; FBLN2S protein was detected in conditioned media of stable transfectants, but not in the vector-alone control (Figure 3a) .
In the in vivo tumorigenicity assay, large tumors formed in nude mice after a 4-to 5-week latency period in the vector-alone control V7 ( ± dox). Significantly suppressed tumorigenicity was observed with two FBLN2S stable transfectants (-dox) (S15 and S18). The tumorigenicity of FBLN2S stable transfectants was restored to vector-alone levels, when FBLN2S expression was switched off in the presence of dox (Figure 3c ). The difference in growth kinetics between T11  T12  T48  T49  T50  T51  T53  T55  T56  T57  T58  T59  T61  T62  T67  T68  T70  T72  T73  T74  T75  T77  T78  T81  T84  T85  T86  T87  T89  T95   Fold differences   HONE1   HK1  HNE1  CNE1  CNE2  C666  SUNE1  NP69  NP460  HONE1   HK1  HNE1  CNE1  CNE2  C666  SUNE1  NP69 Tumor-suppressor gene FBLN2 EWL Law et al the vector-alone control and FBLN2S stable transfectants (±dox) was statistically significant (Supplementary Table S1 ). Clone S8 did not significantly suppress tumor formation. These nude mouse tumors were excised and protein was extracted for western blot analysis of FBLN2S. Loss of FBLN2S expression was detected in all tumors T1-T5, compared with the clone S8 before injection ( Figure 3d ). These results suggest that, unlike the other two tumor-suppressive FBLN2 clones, the tumorigenicity of clone S8 is associated with FBLN2 loss during tumorigenesis.
FBLN2S inhibits in vitro cell proliferation
The in vitro 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide cell growth assay was performed with FBLN2S stable transfectants S8, S15 and the vector-alone control V7 to determine the functional effect of FBLN2S. Inhibition of growth by 57.3 to 64.8% was observed with the S8 and S15 clones (-dox) after 4 days incubation period. Growth rate was restored when FBLN2S expression was switched off with dox treatment (Figure 4a ).
The growth inhibitory effect of secreted FBLN2S was confirmed by culturing the HONE1 cells with the FBLN2S transfectant and vector-alone conditioned media. HONE1 cells cultivated with Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum were used as controls. Growth inhibition of 52.8 to 58.9% was observed in HONE1 cells cultured with conditioned media (-dox) of FBLN2S transfectants, compared with the vector-alone and corresponding þ dox control (Figure 4a ). 
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Re-expression of FBLN2S inhibits NPC cell in vitro migration and invasion In in vitro migration and invasion assays, FBLN2S transfectants S8 and S15 demonstrated 70.9% to 81.5% and 68.5% to 92.9% reduction in both cell migration and invasion, respectively, when compared with vectoralone control V7. When FBLN2S expression was abrogated ( þ dox), the FBLN2S transfectants showed restored migration and invasion abilities. Representative images of the assays are shown (Figures 4b and c) .
FBLN2S inhibits in vitro and in vivo angiogenesis
With FBLN2S stable transfectant conditioned medium (-dox incubation), human umbilical vein endothelial cells (HUVECs) showed 54.5 and 63.3% of the tube formation ability compared with the cells cultivated in vector-alone conditioned medium. In contrast, when HUVECs were cultivated with FBLN2S stable transfectant-conditioned medium ( þ dox), the tube formation ability was restored to levels similar to that of cells cultivated in vector-alone conditioned medium (Figure 5a ).
In the in vivo Matrigel plug assay for FBLN2S stable transfectants S8 and S15, 37.9% and 23.9% reduction of anti-CD34 antibody-stained microvessel signals in nude mouse gel plugs analyzed was observed, respectively, when compared with the vector-alone control V7 (Figure 5b ). Anti-FBLN2 antiserum staining showed FBLN2 expression is still present in the stable transfectant gel plug after 1-week inoculation in nude mice. The result is consistent with HUVEC tube formation assay and suggests FBLN2S has an important role in suppressing angiogenesis of tumor cells to curtail tumor progression.
FBLN2S downregulates pro-angiogenesis factors to inhibit angiogenesis
The molecular pathway in which FBLN2 is involved to regulate angiogenesis was investigated by studying the transcription levels of angiogenesis-related genes, vascular endothelial growth factor (VEGF)165 and VEGF189, matrix metalloproteinase (MMP)2 and MMP9. The FBLN2S stable transfectants showed at least two-fold downregulation of VEGF165, VEGF189 and MMP2, but not MMP9, by Q-PCR analysis (Figure 5c ).
The downregulation of VEGF in FBLN2S stable transfectants was confirmed and quantitated by VEGF enzyme-linked immunosorbent assay. The conditioned medium of vector-alone control (V7 ± dox) shows a high concentration of VEGF (B2600 pg/ml). In conditioned medium of FBLN2S transfectants, the VEGF concentration is reduced to B1500 pg/ml. The VEGF concentration in conditioned medium of FBLN2S stable transfectants was restored to levels similar to the vector-alone control, when FBLN2S expression was switched off by Dox treatment (Figure 5c ). V7-S8-S15+ S15-S18+ S18- 
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Reduced MMP2 enzymatic activities were observed by gelatin zymography in FBLN2S stable transfectants compared with the vector-alone control, while no significant difference of MMP9 enzymatic activities was observed (Figure 5d ). This is consistent with the Q-PCR results of MMP2 and MMP9.
Discussion
Cancer cells are characterized by uncontrolled cell proliferation, ability for migration and invasion, and acquisition of sustained angiogenesis ability (Hanahan and Weinberg 2000) . Loss of FBLN2 expression was reported to be associated with cancer progression, although its functional role in tumor suppression has not been well characterized (Yi et al., 2007; Dunwell et al., 2009; Hill et al., 2010) . Involvement of FBLN2 in NPC development was initially identified by its frequent deletion and methylation detected in the chromosome 3 genomic NotI microarray analysis of NPC cell lines in the present study.
Epigenetic downregulation of FBLN2 was validated in methylation studies. Bisulfite genomic sequencing and methylation-specific PCR analyses consistently detected In vitro functional assay of FBLN2S stable transfectants in cell proliferation, migration and invasion. (a) In vitro growthsuppressive activities of FBLN2S determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide assay. Cell growth inhibition of FBLN2S transfectants and HONE1 cells cultured in conditioned media on day 4 were determined by comparing with the vector-alone control -dox (V7) and untreated HONE1 control (cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum), respectively. *P-value o0.05 indicates statistically significant difference to the þ dox control of the corresponding clone. (b) In vitro migration assays of FBLN2S transfectants and vector-alone control ±dox. Relative migration ability was determined by comparing the area of migrated cells by Â 100 microscopy view to that of vector-alone control þ dox (V7). Representative images of vector-alone control and FBLN2S stable transfectants in the migration assay are shown on the right. (c) In vitro invasion assays in FBLN2S transfectants and vector-alone control ± dox. Relative invasion ability was determined by comparing the area of invaded cells by Â 100 microscopy view to that of vector-alone control þ dox (V7). Representative images of vector-alone control and FBLN2S stable transfectants in the invasion assay are shown on the right. *P-value o0.05 indicates statistically significant difference to the þ dox control of the corresponding clone.
Tumor-suppressor gene FBLN2 EWL Law et al promoter hypermethylation of FBLN2 in NPC cell lines and tumors; FBLN2S expression levels in NPC cell lines were restored after 5-aza-2 0 deoxycytidine treatment. Recent studies also reported the aberrant promoter hypermethylation of FBLN2 in childhood acute lymphoblastic leukemia, lung, colorectal and breast cancers (Dunwell et al., 2009; Hill et al., 2010) . The significant downregulation and frequent promoter hypermethylation of FBLN2S further provides evidence for its involvement in NPC. Allelic loss is common in this chromosome 3p25 region (Nakao et al., 2011) . A continuous homozygous pattern of markers observed in three NPC cell lines, suggested loss of heterozygosity may also contribute to the silencing of FBLN2 expression together with methylation. FBLN2 was also reported to be frequently deleted in esophageal squamous cell carcinoma patients in India (Chattopadhyay et al., 2010) . Relative tube-forming abilities were determined by comparison between the HUVECs cultivated in conditioned medium of FBLN2 transfectants (S8 and S15) and that of vector-alone control þ dox (V7). Representative images of HUVEC cells cultured in conditioned media of vector-alone control and FBLN2S stable transfectants are shown on the right. (b) In vivo Matrigel plug assay of FBLN2S transfectants and vector-alone control. Endothelial cells were stained with anti-CD34 antibody. CD34 staining index was determined by comparison between the CD34 staining index of FBLN2S transfectants (S8 and S15) to that of the vector-alone control (V7). Representative images of histological section of slides stained with anti-CD34 and anti-FBLN2 antibody are shown. (c) Q-PCR analysis of angiogenesis-related genes and enzyme-linked immunosorbent assay (ELISA) assay of VEGF of FBLN2S stable transfectants. Fold differences of the gene expression levels were compared with that of the vector-alone control (V7) by Q-PCR. Glyceraldehyde 3-phosphate dehydrogenase served as an internal control. Reduced VEGF and MMP2 expression was observed in FBLN2S stable transfectants by Q-PCR analysis. The downregulation of VEGF was confirmed by the ELISA assay (right). (d) Zymography of vector-alone control and FBLN2S stable transfectant conditioned media. Relative MMP2 activity of each clone (S8 and S15) was compared with that of the vector-alone control (V7). Total protein stained with coomassie blue served as the normalization controls. A representative zymography result is shown. MMP9 and MMP2 are indicated. Relative MMP2 activities of S8 and S15 are compared with V7. *P-value o0.05 indicates statistically significant difference to the vector-alone control.
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The in vivo nude mouse tumorigenicity assays clearly show that expression of FBLN2S is able to induce potent tumor suppression in NPC. One transfectant, however, which had lost FBLN2 protein expression in vivo, was unable to suppress tumors after inoculation and selection in nude mice, as observed in previous nude mouse assays for other TSGs . To date, this is the first report to provide in vivo functional evidence that FBLN2 is a potent suppressor of tumor formation in NPC.
FBLN2S contributes to in vivo tumor suppression through cell proliferation inhibition and angiogenesis suppression. Transient transfection of FBLN2S suppressed the colony formation ability of the NPC cell lines. Consistently, expression of FBLN2S protein strongly inhibits proliferation. The growth inhibition of secreted FBLN2S was observed in the HONE1 cells cultivated with the FBLN2S transfectant conditioned medium. FBLN2 is a secreted ECM protein, which interacts with diverse ECM proteins involved in remodeling and stabilization of the ECM during organ development (de Vega et al., 2009) . These interactions between secreted FBLN2 and ECM proteins may contribute to the NPC development.
The acquisition of sustained angiogenesis is essential for both tumor growth and metastasis. In vivo angiogenesis and HUVEC tube formation assays show that FBLN2 can inhibit angiogenesis and contributes to in vivo tumor suppression. Q-PCR of angiogenesisrelated genes showed that VEGF is downregulated in the FBLN2S transfectants. The reduced VEGF expression was confirmed by VEGF enzyme-linked immunosorbent assay. Downregulation of MMP2 was also observed in the transfectants by zymography and Q-PCR. The stimulation of MMP2 by VEGF has been reported in endothelial progenitor cells; knockdown of MMP2 by small interfering RNA and suppression of MMP2 by kininogen inhibits tube formation of endothelial progenitor cells in vitro (Wu et al., 2010) . Downregulation of MMP2, which contributes to the angiogenesis inhibition of the FBLN2S stable transfectants, may be associated with the reduced expression of VEGF. FBLN2 involvement in angiogenesis inhibition has not yet been reported in NPC studies. Reduced expression of VEGF and MMP2 likely induces angiogenesis inhibition, but elucidation of the detailed mechanisms of FBLN2-inducing downregulation of these factors requires further study.
Expression of FBLN2 reduced cellular migration and invasion abilities in NPC. In another study of the association between FBLN2 expression and breast cancer progression, transfection of FBLN2 into breast cancer cell lines also reduced the cell migration and invasion abilities in vitro (Yi et al., 2007) . MMP2, which is a potent gelatinase, cleaves the protein components of the ECM and is involved in the processes of tumor cell invasion and metastasis (McDonnell and Matrisian 1990; Libra et al., 2009) . The decreased MMP2 activities in FBLN2S transfectants provide an explanation and evidence for the invasion suppression by FBLN2S. FBLN2 is known to interact with many ECM proteins and serves as a scaffold protein for ECM (de Vega et al., 2009) . Decreased expression of FBLN2 may lead to disruptions in the molecular architecture of the ECM and basement membrane and subsequently provide enhanced opportunities for the tumor cells to migrate and invade through these disrupted structures. FBLN2 also interacts with the proteins, which may have a common role in migration and invasion. Integrins are important adhesion proteins in normal tissues. There is a group of integrins that are related to the migration and invasion of cancer cells (Rathinam and Alahari 2010) . Integrin aVb3 interacts with FBLN2 and is related to metastatic tumor progression (Pfaff et al., 1995) . The interaction between FBLN2 and versican is important for smooth muscle cell migration. Blocking their interaction inhibits the in vitro migration of smooth muscle cells (Strom et al., 2006) . Understanding the possible interaction among ECM proteins may provide a fuller picture for the mechanism of FBLN2-associated migration and invasion suppression.
In conclusion, FBLN2S expression is clearly able to inhibit in vitro cell proliferation, angiogenesis and migration and invasion in NPC. Furthermore, the in vivo tumorigenicity assay provides compelling evidence for a potent tumor-suppressive role of FBLN2S in NPC.
Materials and methods
Cell culture
Seven NPC cell lines (HONE1, HK1, HNE1, CNE1, CNE2, C666 and SUNE1), the immortalized NP epithelial cell lines (NP69 and NP460) (Zhang et al., 2004; Li et al., 2006) , and HUVECs (Lonza, Basel, Switzerland) were cultured as previously described . A tetracycline-controlled transcriptional activator tTA-producing cell line, HONE1-2, was used for FBLN2S stable transfection .
NPC tissue specimens
Matched normal NP and NPC biopsies from 30 NPC patients were collected from Queen Mary Hospital in Hong Kong from 2006 to 2009, as previously described (Cheung et al., 2008) . All the biopsies were immediately stored in RNAlater solution (Ambion, Austin, TX, USA). The study protocol was approved by the Hospital Institutional Review Board. Written consents were obtained from all patients. All biopsies were verified histologically for tumor identification.
NotI chromosome 3 genomic microarray analysis NotI microarray hybridization and NotI digestion were performed, as previously described, using 182 chromosome 3-specific NotI linking clones (GE Healthcare) according to the manufacturer's recommendations. Automatic washing of the microarrays was performed in the same device according to the manufacturer's recommendations. The following solutions were sequentially used for washing: 1, 0.2% sodium dodecyl sulfate, 1X saline-sodium citrate; 2, 0.2% sodium dodecyl sulfate, 0.1X saline-sodium citrate; 3, 0.1X salinesodium citrate; 4, deionized water; 5, isopropyl alcohol.
The NP69 immortalized normal NP epithelial cell line was compared with HONE1, HK1 and C666 NPC cell lines. Three tumor-suppressive NPC HONE1 MCHs containing either an exogenously transferred intact or truncated chromosome 3 were utilized. MCH4.6 contains an extra intact exogenous chromosome 3. The exogenous chromosome 3 of MCH8.12, with a discrete deletion in the 3p24.2-3p22 region, and MCH12.10 containing an exogenous chromosome 3 harboring a significant deletion in 3pter-3p22 region were used. These cell line complementary DNAs were hybridized against their matched tumorigenic tumor segregants arising after selection in the mice (Cheng et al, 1998) . Microarrays were scanned in a GenePix 4000A. The results were processed with GenePix Pro 6.0 software (GE Healthcare).
RT-PCR and real-time Q-PCR analysis
One microgram of total RNA was reverse transcribed with M-MLV Reverse Transcriptase (USB, Cleverland, OH, USA), as previously described (Cheung et al., 2009) . The expression of long and short isoforms of FBLN2 in NPC cell lines and tumor biopsies was analyzed by RT-PCR. Q-PCR was performed as previously described (Cheung et al., 2008) in a Step-One Plus machine using SYBR-green PCR core reagent kits (Applied Biosystems, Foster City, CA, USA). We analyzed expression of FBLN2, MMP2, MMP9 and VEGF using gene-specific primers (Supplementary Table S2 ). Glyceraldehyde 3-phosphate dehydrogenase was used as an internal control. Assays were performed in duplicate and repeated twice.
Western blot analysis
Western blot analysis of FBLN2 was performed as previously described (Cheung et al., 2008) . Polyclonal antiserum against the full-length FBLN2 protein was prepared as described (Pan et al., 1993) . The a-tubulin antibody Ab-1 (1:10 000; Merck, Darmstadt, Germany) was used as a normalization control.
Methylation analysis
Bisulfite modification of DNA was performed as previously described (Cheung et al., 2008) . The 591-bp putative FBLN2 CpG island in the promoter region mapping to position chr3:13565415-13566008 has been described (Supplementary Figure S1 ; Dunwell et al., 2009) . The methylation status of FBLN2 was determined by bisulfite genomic sequencing and methylation-specific PCR. Semi-nested bisulfite PCR primers were used to amplify regions of the CpG island in the promoter region as previously described (Dunwell et al., 2009) . PCR products were sequenced to determine the MI of samples. The MI was calculated according to the following formula: MI % ¼ number of CpG sites methylated/total number of CpG sites sequenced Â 100%. FBLN2 methylation-specific PCR primers overlapping with the bisulfite genomic sequencing regions were designed according to the MethPrimer guide.
5-Aza-2
0 -deoxcycytidine treatment Seven NPC cell lines were treated with 5 mmol/l 5-aza-2 0 -deoxycytidine (Sigma, St Louis, MO, USA) for 5 days, as previously described (Cheung et al., 2008) . Alteration in the expression levels of FBLN2 in the treated cell lines was determined by RT-PCR of RNAs prepared from 5-day treated cells.
Microsatellite typing analysis
Five overlapping and nearby FBLN2 microsatellite markers were used to investigate allelic loss (Supplementary Table S3 ). Microsatellite typing of amplicons was performed using semi-automated fluorescent PCR-based analysis (Applied Bio Systems Prism 3100 Genetic Analyzer) utilizing Genemapper version 3.0 software (Applied Biosystems, Foster City, CA, USA), as previously described (Cheung et al., 2008) .
Transient transfection and colony formation assay
The full-length open reading frame of the FBLN2S was amplified from the non-tumorigenic immortalized NP epithelial cell line, NP460, and cloned into pCR3.1 (Invitrogen). After sequencing validation, plasmids were transfected into NPC cell lines with Lipofectamine 2000 reagent (Invitrogen) and colony formation assays were performed, as previously described (Cheung et al., 2008) . Each assay was performed in duplicate and repeated twice.
Stable transfection of FBLN2S
The pETE-blasticidin vector containing a cytomegalovirus promoter, which is tetracycline-regulated , was used to establish FBLN2S stable clones. The FBLN2 fragment in pCR3.1 was excised and ligated into the pETE-blasticidin vector for transfection into the tetracyclineregulated cell line, HONE1-2. Clones were selected and screened for FBLN2S-positive clones, as previously described (Cheung et al., 2009) .
In vivo tumorigenicity assay The tumorigenicity of cell lines was assayed by subcutaneous injection, as previously described . For inhibition of the tetracycline-inducible expression of FBLN2 in vivo, 200 mg/ml Dox was added into the mouse drinking water . For investigating the FBLN2 expression within tumors subsequently arising from FBLN2 stable transfectants, the tumors were excised from mice for RNA and protein extraction for further analysis.
In vitro cell growth analysis The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide assay of the FBLN2 transfectants and the vector-alone control ± 0.2 ı`g/ml dox was performed, as previously described . Conditioned medium of stable clones was collected from the serum-free Dulbecco's modified Eagle's medium used to cultivate cells for 24 h. The absorbance of reduced 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide in samples was measured at 570 nm. Measurement of cell growth by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay was expressed as percent inhibition according to the following formula: % inhibition ¼ ((absorbance of vector-alone controlsÀabsorbance of FBLN2 transfectants)/absorbance of vector-alone controls) Â 100%. The assay was performed in duplicate and repeated twice.
